FEMY on Nasdaq
FEMASYS INC
We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and.3 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with QHSLab, Inc., VYCOR MEDICAL INC or OSR Health, Inc., or pick any stock.
- TickerFEMY on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersSuwanee, Georgia1
- Incorporated inDE2
- Business address3950 Johns Creek Court, Suite 100, Suwanee, Ga 300242
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets. FemaSeed ® Intratubal Insemination, a groundbreaking first-step infertility treatment delivering sperm directly to the site of conception, is U.S. FDA-cleared and approved in Europe, United Kingdom (UK), Canada, Israel, Australia and New Zealand. A peer-reviewed publication of positive data from its pivotal clinical trial of FemaSeed demonstrated effectiveness and safety with high satisfaction from both patients and practitioners. FemSperm ® , which includes setup, preparation and analys…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-767.0%Operating margin4
-812.3%Net margin4
40.8%Revenue growth, 20254
-317.4%Return on equity4
-$19.2MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 61% of the revenue FEMASYS INC broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $1.1M | $1.4M |
| Outside the United States | $555.6K | $899.8K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue10¢$872.4K
- Research and development90¢$7.6M
- Income tax0¢$1.3K
Out of $2.3M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | $2.3M | $1.6M |
| Cost of sales (excluding depreciation expense) | $872.4K | $544.9K |
| Research and development | $7.6M | $8.2M |
| Sales and marketing | $4.4M | $4.0M |
| General and administrative | $6.6M | $6.3M |
| Depreciation and amortization | $342.0K | $297.3K |
| Total operating expenses | $19.0M | $18.9M |
| Loss from operations | -$17.6M | -$17.8M |
| Interest income | $101.8K | $582.4K |
| Change in fair value of conversion option liability | $503.0K | $0 |
| Change in fair value of warrants liabilities | $731.0K | $0 |
| Interest expense | -$1.9M | -$1.6M |
| Other expense | -$482.6K | $0 |
| Total other expense, net | -$1.0M | -$1.0M |
| Loss before income taxes | -$18.6M | -$18.8M |
| Income tax expense | $1.3K | $9.6K |
| Net loss | -$18.6M | -$18.8M |
| Net loss attributable to common stockholders, basic | -$18.6M | -$18.8M |
| Net loss attributable to common stockholders, diluted | -$18.6M | -$18.8M |
| Net loss per share attributable to common stockholders, basic (in Dollars per share) | -$0.47 | -$0.85 |
| Net loss per share attributable to common stockholders, diluted (in Dollars per share) | -$0.47 | -$0.85 |
| Weighted-average common shares and pre-funded warrants outstanding- basic (in Shares) | 39.5M shares | 22.3M shares |
| Weighted-average common shares and pre-funded warrants outstanding- Diluted (in Shares) | 39.5M shares | 22.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $9.3M | $3.5M | |
| Accounts receivable, net | $616.6K | $488.4K | |
| Inventory | $5.7M | $3.0M | |
| Prepaid and other current assets | $833.1K | $1.0M | |
| Total current assets | $16.5M | $8.0M | |
| Leasehold improvements | $1.2M | $1.2M | |
| Office equipment | $78.2K | $60.9K | |
| Furniture and fixtures | $417.9K | $417.9K | |
| Machinery and equipment | $3.1M | $2.9M | |
| Construction in progress | $897.9K | $762.4K | |
| Property and equipment, gross | $5.7M | $5.3M | |
| Less accumulated depreciation | -$3.8M | -$3.7M | |
| Net property and equipment | $1.9M | $1.6M | |
| Lease right-of-use assets, net | $1.3M | $1.8M | |
| Intangible assets, net of accumulated amortization | $134.9K | $65.9K | |
| Other long-term assets | $940.2K | $955.0K | |
| Total long-term assets | $2.4M | $2.8M | |
| Total assets | $20.7M | $12.4M | |
| Accounts payable | $1.8M | $1.4M | |
| Accrued expenses | $1.3M | $1.2M | |
| Convertible notes payable, net (including related parties) | $0 | $5.4M | |
| Clinical holdback current portion | $52.6K | $88.6K | |
| Operating lease liabilities current portion | $487.6K | $518.0K | |
| Total current liabilities | $3.6M | $8.6M | |
| Clinical holdback long-term portion | $52.4K | $39.6K | |
| Convertible notes payable, net | $3.2M | $0 | |
| Conversion option liability | $2.0M | $0 | |
| Warrants liabilities | $4.9M | $0 | |
| Operating lease liabilities long-term portion | $1.0M | $1.5M | |
| Total long-term liabilities | $11.2M | $1.6M | |
| Total liabilities | $14.9M | $10.1M | |
| Common stock, $0.001 par, 200,000,000 authorized,59,720,010 shares issued and 59,602,787 outstanding as of December 31, 2025; and 23,473,149 shares issued and 23,355,926 outstanding as of December 31, 2024 | $59.7K | $23.5K | |
| Treasury stock, 117,223 common shares | -$60.0K | -$60.0K | |
| Warrants | $5.2M | $1.9M | |
| Additional paid-in-capital | $146.4M | $127.7M | |
| Accumulated deficit | -$145.8M | -$127.2M | |
| Total stockholders equity | $5.9M | $2.3M | $18.4M |
| Total liabilities and stockholders' equity | $20.7M | $12.4M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in Shares) | 200.0M shares | 200.0M shares | |
| Common stock, issued (in Shares) | 59.7M shares | 23.5M shares | |
| Common stock, outstanding (in Shares) | 59.6M shares | 23.4M shares | |
| Treasury stock, common shares (in Shares) | 117.2K shares | 117.2K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $9.3M | $3.5M | |
| Accounts receivable, net | $616.6K | $488.4K | |
| Inventory | $5.7M | $3.0M | |
| Prepaid and other current assets | $833.1K | $1.0M | |
| Total current assets | $16.5M | $8.0M | |
| Leasehold improvements | $1.2M | $1.2M | |
| Office equipment | $78.2K | $60.9K | |
| Furniture and fixtures | $417.9K | $417.9K | |
| Machinery and equipment | $3.1M | $2.9M | |
| Construction in progress | $897.9K | $762.4K | |
| Property and equipment, gross | $5.7M | $5.3M | |
| Less accumulated depreciation | -$3.8M | -$3.7M | |
| Net property and equipment | $1.9M | $1.6M | |
| Lease right-of-use assets, net | $1.3M | $1.8M | |
| Intangible assets, net of accumulated amortization | $134.9K | $65.9K | |
| Other long-term assets | $940.2K | $955.0K | |
| Total long-term assets | $2.4M | $2.8M | |
| Total assets | $20.7M | $12.4M | |
| Accounts payable | $1.8M | $1.4M | |
| Accrued expenses | $1.3M | $1.2M | |
| Convertible notes payable, net (including related parties) | $0 | $5.4M | |
| Clinical holdback current portion | $52.6K | $88.6K | |
| Operating lease liabilities current portion | $487.6K | $518.0K | |
| Total current liabilities | $3.6M | $8.6M | |
| Clinical holdback long-term portion | $52.4K | $39.6K | |
| Convertible notes payable, net | $3.2M | $0 | |
| Conversion option liability | $2.0M | $0 | |
| Warrants liabilities | $4.9M | $0 | |
| Operating lease liabilities long-term portion | $1.0M | $1.5M | |
| Total long-term liabilities | $11.2M | $1.6M | |
| Total liabilities | $14.9M | $10.1M | |
| Common stock, $0.001 par, 200,000,000 authorized,59,720,010 shares issued and 59,602,787 outstanding as of December 31, 2025; and 23,473,149 shares issued and 23,355,926 outstanding as of December 31, 2024 | $59.7K | $23.5K | |
| Treasury stock, 117,223 common shares | -$60.0K | -$60.0K | |
| Warrants | $5.2M | $1.9M | |
| Additional paid-in-capital | $146.4M | $127.7M | |
| Accumulated deficit | -$145.8M | -$127.2M | |
| Total stockholders equity | $5.9M | $2.3M | $18.4M |
| Total liabilities and stockholders' equity | $20.7M | $12.4M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in Shares) | 200.0M shares | 200.0M shares | |
| Common stock, issued (in Shares) | 59.7M shares | 23.5M shares | |
| Common stock, outstanding (in Shares) | 59.6M shares | 23.4M shares | |
| Treasury stock, common shares (in Shares) | 117.2K shares | 117.2K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$18.6M | -$18.8M |
| Depreciation | $295.9K | $277.2K |
| Amortization | $46.2K | $20.1K |
| Other noncash items | $5.7K | $0 |
| Change in fair value of conversion option liability | -$503.0K | $0 |
| Change in fair value of warrants liabilities | -$731.0K | $0 |
| Amortization of right-of-use assets | $508.4K | $574.7K |
| Loss on fixed asset dispositions | $62.6K | $676 |
| Share-based compensation expense | $790.1K | $444.1K |
| Amortization of debt issuance costs and discount | $1.4M | $1.2M |
| Accretion of paid-in-kind interest | $132.1K | $0 |
| Accounts receivable | -$128.2K | -$389.5K |
| Inventory | -$2.7M | -$2.4M |
| Prepaid and other assets | $496.9K | -$139.1K |
| Accounts payable | $334.8K | $207.5K |
| Accrued expenses | $474.7K | $6.8K |
| Lease liabilities | -$518.0K | -$406.6K |
| Other liabilities | -$23.2K | -$36.6K |
| Net cash used in operating activities | -$18.7M | -$19.4M |
| Acquisition of patents | -$105.1K | -$86.1K |
| Purchases of property and equipment | -$525.0K | -$761.7K |
| Net cash used in investing activities | -$630.1K | -$847.8K |
| Proceeds from exercise of pre-funded warrants | $500 | $0 |
| Proceeds from exercise of common warrants | $3.3M | $0 |
| Proceeds from November 2025 convertible notes | $12.0M | $0 |
| Issuance costs for November 2025 convertible notes | -$718.5K | $0 |
| Proceeds from common stock issued through ESPP | $90.3K | $63.1K |
| Proceeds from at-the-market sales of common stock | $7.0M | $2.0M |
| Issuance costs for at-the-market sales of common stock | -$210.4K | -$60.8K |
| Repayment of November 2023 convertible notes, including related parties | -$6.8M | $0 |
| Repayment of note payable | -$367.4K | $0 |
| Net cash provided by financing activities | $25.1M | $2.0M |
| Net change in cash and cash equivalents | $5.8M | -$18.3M |
| Interest | $8.6K | $111.0K |
| Income taxes | $6.8K | $5.7K |
| Property and equipment costs included in accounts payable and accrued expense | $60.4K | $73.7K |
| Acquisition of patents included in accounts payable | $15.8K | $0 |
| Conversion of November 2023 convertible notes into common stock | $85.0K | $0 |
| Payment of November 2023 convertible note interest in common stock | $360.0K | $300.0K |
| Deferred offering costs reclassified to additional paid-in-capital | $15.6K | $3.1K |
| Fair value of conversion option liability at November 2025 issuance | $2.5M | $0 |
| Fair value of warrants liabilities at November 2025 issuance | $5.7M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led FEMASYS INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerKathy Lee-Sepsick Jun 17, 2021 to now11
- Chief financial officerDov Elefant Mar 1, 2022 to now12
- Chief operating officerJohn Charles Canning Apr 1, 2026 to now13
- Chief operating officerDaniel Scott Currie Feb 2, 2024 to Apr 1, 202614
Board members and other officers (16)
- Chief Technology OfficerJeremy Alexander Sipos Feb 17, 2026 to now15
- Chief Clinical-Medical AffairsJeffrey Gerald Mifek Aug 11, 2026 to now16
- Chief Commercial OfficerKelley Stinson Nicholas Jul 1, 2025 to now17
- Chief Commercial OfficerRichard D. Spector Feb 13, 2024 to Feb 13, 202418
- Senior VP, OperationsDaniel Scott Currie Jun 17, 2021 to Jul 3, 202319
- VP, Clinical & Medical AffairsHoskin Violet Alexandria Kelley Jun 17, 2021 to Jun 17, 202120
- Chief Medical OfficerEdward Evantash Sep 9, 2021 to Sep 9, 202121
- Board memberKenneth D. Eichenbaum Mar 20, 2026 to now22
- Board memberAlistair Milnes Jun 16, 2023 to now23
- Board memberKeith J. Kendall Jun 16, 2023 to Jun 16, 202324
- Board memberWendy Perrow Jan 20, 2022 to Jun 23, 202325
- Board memberAnne Morrissey Jun 17, 2021 to Jun 23, 202326
- Board memberEdward R. Uzialko Jun 17, 2021 to now27
- Board memberJohn Dyett Jun 17, 2021 to Jun 10, 202228
- Board memberKathy Lee-Sepsick Jun 17, 2021 to now11
- Board memberWilliam Benson Witte Jun 17, 2021 to Dec 17, 202129
Named in SEC Form D filings
People the company listed in its private-offering notices.
Timeline
- Jun 17, 2021New chief executive Kathy Lee-Sepsick becomes CEO11
Filings
286 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 93 major events, 85 insider forms, 11 large holders, 4 private raises, 70 other. The latest 20:
- Oct 15, 2026SCHEDULE 13G EDGAR
- Sep 29, 2026424B3 EDGAR
- Sep 28, 2026EFFECT EDGAR
- Sep 3, 2026S-3 EDGAR
- Aug 31, 2026SCHEDULE 13G EDGAR
- Aug 20, 2026D EDGAR
- Aug 17, 2026SCHEDULE 13D EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 14, 20268-K EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20263 EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20264 EDGAR
The 286 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Mifek Jeffrey GeraldChief Clinical-Medical Affairs | Buy | 3,125 | $3.20 | $10.0K | Form 4 |
| Aug 7, 2026 | Sipos Jeremy AlexanderChief Technology Officer | Buy | 3,125 | $3.20 | $10.0K | Form 4 |
| Aug 7, 2026 | Canning John CharlesChief Operating Officer | Buy | 4,375 | $3.20 | $14.0K | Form 4 |
| Aug 7, 2026 | Elefant DovChief Financial Officer | Buy | 15,625 | $3.20 | $50.0K | Form 4 |
| Aug 7, 2026 | Lee-Sepsick KathyChief Executive Officer | Buy | 15,625 | $3.20 | $50.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Empery Asset Management, LPSCHEDULE 13G, 1 filing Oct 15, 202632
- Stonepine Capital Management, LLCSCHEDULE 13G, 1 filing Aug 31, 202633
- Nantahala Capital Partners Limited PartnershipSCHEDULE 13D, 1 filing Aug 17, 202634
- Rosalind Advisors, Inc.SCHEDULE 13G, 1 filing Aug 14, 202635
- Dauntless Investment Group, LLCSCHEDULE 13G/A, 2 filings Feb 26, 2025 to Nov 14, 202536
- Alumni Capital LPSCHEDULE 13G, 1 filing Sep 4, 202537
- Jorey ChernettSCHEDULE 13G/A, 2 filings Feb 26, 2025 to Aug 5, 202538
Money raised
Private offerings the company reported to the SEC on Form D.
- Aug 10, 2026Raised $30 million in a private offering of equity Form D: 41 investors so far Form D
- Nov 7, 2025Raised $8 million in a private offering of debt Form D: $12 million offered in all Form D
- Jun 2, 2025Raised $1.4 million in a private offering of equity Form D: 6 investors so far Form D
- Nov 14, 2023Raised $6.8 million in a private offering of debt Form D: 4 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Dauntless Investment Group, LLC | 1,867,987 | $7.8M | 13.5% | New |
| Vanguard Capital Management LLC | 62,232 | $260.1K | 0.0% | New |
| Jane Street Group, LLC | 52,511 | $219.5K | 0.0% | New |
| Geode Capital Management, LLC | 30,920 | $129.3K | 0.0% | New |
| UBS Group AG | 18,777 | $78.5K | 0.0% | New |
| Citadel Advisors LLC | 16,921 | $70.7K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 12,492 | $52.2K | 0.0% | New |
| Osaic Holdings, Inc. | 2,397 | $10.0K | 0.0% | New |
| BlackRock, Inc. | 1,784 | $7.5K | 0.0% | New |
| Northwestern Mutual Wealth Management Co | 1,000 | $4.2K | 0.0% | New |
| Arax Advisory Partners | 900 | $3.8K | 0.0% | New |
| Whittier Trust Co Of Nevada Inc | 794 | $3.1K | 0.0% | New |
| Trust Co Of Toledo Na /oh/ | 87 | $364 | 0.0% | New |
| IFP Advisors, Inc | 50 | $209 | 0.0% | New |
| Barclays PLC | 8 | $33 | 0.0% | New |
| SBI Securities Co., Ltd. | 7 | $29 | 0.0% | New |
| Morgan Stanley | 3 | $13 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARFEMASYS INC filings on SEC EDGAR
- 2SEC EDGARFEMASYS INC filings on SEC EDGAR
- 3
- 4SEC EDGARFEMASYS INC 10-K for fiscal 2025
- 5SEC EDGARFEMASYS INC 10-K for fiscal 2020
- 6SEC EDGARFEMASYS INC 10-K for fiscal 2021
- 7SEC EDGARFEMASYS INC 10-K for fiscal 2022
- 8SEC EDGARFEMASYS INC 10-K for fiscal 2023
- 9SEC EDGARFEMASYS INC 10-Q for fiscal 2026
- 10SEC EDGARFEMASYS INC 10-Q for fiscal 2026
- 11
- 12SEC EDGARDov Elefant, Chief financial officer
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARKenneth D. Eichenbaum, Board member
- 23SEC EDGARAlistair Milnes, Board member
- 24SEC EDGARKeith J. Kendall, Board member
- 25SEC EDGARWendy Perrow, Board member
- 26SEC EDGARAnne Morrissey, Board member
- 27SEC EDGAREdward R. Uzialko, Board member
- 28SEC EDGARJohn Dyett, Board member
- 29SEC EDGARWilliam Benson Witte, Board member
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38